Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC69648p53 Activator 7CAS: 2849340-59-4纯度: >98.00%
p53 Activator 7 是一种 p53 突变 Y220C (MDM-2/p53) 激活剂,EC50 为 104 nM。p53 Activator 7 可以结合 p53 突变体并恢复其结合 DNA 的能力 (WO2022213975A1; Example B-1)。
- GC69673PD-1/PD-L1-IN-13
PD-1/PD-L1-IN-13 (Compound 43) 是一种有效的免疫检查点 PD-1/PD-L1 抑制剂,对 PD-1/PD- L1 相互作用的 IC50 值为 10.2 nM。PD-1/PD-L1-IN-13 在 Hepa1-6 同系小鼠模型中促进 CD8+ T 细胞活化并延缓肿瘤生长。
- GC69674PD-1/PD-L1-IN-14CAS: 2499965-12-5
PD-1/PD-L1-IN-14 (compound 17) 是 PD-1/PD-L1 相互作用的抑制剂,其IC50 值为 27.8 nM。PD-1/PD-L1-IN-14 (compound 17) 抑制PD-1/PD-L1 相互作用,促进二聚化,内吞作用并降解 PD-L1。
- GC69676PD-1/PD-L1-IN-29CAS: 2665734-13-2纯度: >98.00%
PD-1/PD-L1-IN-29(S4-1)是一种有效的 PD-1/PD-L1 抑制剂,其 IC50 值为 6.1 nM。 PD-1/PD-L1-IN-29 可以结合 PD-L1 并破坏 PD -1/PD-L1 相互作用,诱导 PD-L1 二聚化和内化,改善其对内质网的定位,促进 PD-L1 进入内质网。 PD-1/PD-L1-IN-29 具有抗癌活性。
- GC69705Physalin ACAS: 23027-91-0
Physalin A 是一种从 Physalis alkekengi var franchetii 中分离出来的 withanolide。 Physalin A 诱导细胞凋亡 (apoptosis) 与 caspase-3 和 caspase-8 表达上调相关的。Physalin A 诱导自噬,发现可拮抗 HT1080 细胞的凋亡。Physalin A具有研究癌症疾病的潜力。
- GC69795(Rac)-BIO8898CAS: 402564-79-8
(Rac)-BIO8898 是一种 CD40-CD154 共刺激相互作用抑制剂。(Rac)-BIO8898 抑制 CD154 与 CD40-Ig 结合,IC50 为 25 μM。
- GC69801RagifilimabCAS: 2207590-51-8纯度: >95.00%
Ragifilimab (INCAGN-1876) 是一种靶向糖皮质激素诱导的 TNFR 相关蛋白 (GITR) 的激动剂单克隆抗体。Ragifilimab 可用于晚期或转移性实体瘤研究。
- GC69841RubropunctatinCAS: 514-67-0纯度: >98.00%
Rubropunctatin 是一种从红曲霉发酵米(红霉米)提取物中分离出来的橙色的氮杂酮类色素。 Rubropunctatin 具有抗炎,免疫抑制和抗氧化作用,还具有抗肿瘤活性。
- GC69884Shepherdin (79-87) (TFA)纯度: >98.00%
Shepherdin (79-87) TFA 是 Shepherdin 的 79 至 87 氨基酸片段。Shepherdin 是一种 Hsp90-Survivin 复合物的拟肽拮抗剂。具有抗肿瘤活性。
- GC69899SIRT6 activator 12qCAS: 2601734-99-8纯度: >98.00%
SIRT6 activator 12q是一种SIRT6选择性激活剂(IC 50 =0.58μM)。
- GC69912SLC7A11-IN-1纯度: >95.00%
SLC7A11-IN-1 是一种有效的SLC7A11 抑制剂。SLC7A11-IN-1 显示出抗增殖活性。SLC7A11-IN-1 抑制细胞侵袭和转移。SLC7A11-IN-1 诱导细胞凋亡 (Apoptosis) 和细胞周期停滞在 S 期。SLC7A11-IN-1 具有抗肿瘤活性。
- GC69934SpartalizumabCAS: 1935694-88-4纯度: >98.00%
Spartalizumab (PDR001) 是一种人源化的免疫球蛋白 4 单克隆抗体,以亚纳摩尔活性结合 PD-1,并阻断与 PD-L1 和 PD-L2 的相互作用。Spartalizumab 可用于甲状腺未分化癌 (ATC) 的研究。
- GC69968SulanemadlinCAS: 1451199-98-6纯度: >95.00% / >96.50%
Sulanemadlin是一种基于p53靶点的膜渗透性强效大环拟肽化合物,是一种稳定的α-螺旋肽。
- GC70026Thymidine 3',5'-diphosphate tetrasodiumCAS: 118675-87-9纯度: >97.00%
Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium 是葡萄球菌核酸酶和含有 1 的都铎结构域 (SND1,MicroRNA 调控复合体 RISC 亚基) 与 [3,5-2H2] 酪氨酸核酸酶 ( [3,5-2H2] tyrosyl nuclease) 的选择性抑制剂。Thymidine 3',5'-diphosphate tetrasodium 具有抗肿瘤活性,在生化反应也可用作催化剂。
- GC70104UtomilumabCAS: 1417318-27-4纯度: >99.00%
Utomilumab (PF 05082566) 是一种人源化的 IgG2 mAb 激动剂,靶向T 细胞共刺激受体 4-1BB/CD137。Utomilumab 可用于复发/难治性滤泡性淋巴瘤 (FL) 和其他 CD20+ 非霍奇金淋巴瘤 (NHL) 的研究。
- GC70114Venetoclax-d8CAS: 1257051-06-1纯度: >99.00%
Venetoclax-d8 是 Venetoclax 氘代物。Venetoclax (ABT-199; GDC-0199) 是一种高效,有选择性和口服有效的 Bcl-2 抑制剂,Ki 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。
- GC70154Yakuchinone ACAS: 78954-23-1纯度: >97.00%
Yakuchinone A 是一种可以从 Alpinia oxyphylla 果实分离得到的天然产物,可以诱导细胞凋亡 (apoptosis),具有抗癌、抗炎活性。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC69648 | p53 Activator 7 | 2849340-59-4 | >98.00% | |
p53 Activator 7 是一种 p53 突变 Y220C (MDM-2/p53) 激活剂,EC50 为 104 nM。p53 Activator 7 可以结合 p53 突变体并恢复其结合 DNA 的能力 (WO2022213975A1; Example B-1)。 | ||||
| GC69673 | PD-1/PD-L1-IN-13 | - | - | |
PD-1/PD-L1-IN-13 (Compound 43) 是一种有效的免疫检查点 PD-1/PD-L1 抑制剂,对 PD-1/PD- L1 相互作用的 IC50 值为 10.2 nM。PD-1/PD-L1-IN-13 在 Hepa1-6 同系小鼠模型中促进 CD8+ T 细胞活化并延缓肿瘤生长。 | ||||
| GC69674 | PD-1/PD-L1-IN-14 | 2499965-12-5 | - | |
PD-1/PD-L1-IN-14 (compound 17) 是 PD-1/PD-L1 相互作用的抑制剂,其IC50 值为 27.8 nM。PD-1/PD-L1-IN-14 (compound 17) 抑制PD-1/PD-L1 相互作用,促进二聚化,内吞作用并降解 PD-L1。 | ||||
| GC69675 | PD1-PDL1-IN 1 TFA | - | >95.00% | |
PD1-PDL1-IN 1 TFA是一种强效的程序性死亡受体1(PD-1)抑制剂,可用作免疫调节剂。 | ||||
| GC69676 | PD-1/PD-L1-IN-29 | 2665734-13-2 | >98.00% | |
PD-1/PD-L1-IN-29(S4-1)是一种有效的 PD-1/PD-L1 抑制剂,其 IC50 值为 6.1 nM。 PD-1/PD-L1-IN-29 可以结合 PD-L1 并破坏 PD -1/PD-L1 相互作用,诱导 PD-L1 二聚化和内化,改善其对内质网的定位,促进 PD-L1 进入内质网。 PD-1/PD-L1-IN-29 具有抗癌活性。 | ||||
| GC69677 | MAX-10181 | 2171558-14-6 | >98.00% | |
MAX-10181 (PD-1/PD-L1-IN-30) 是一种 PD-1/PD-L1 结合抑制剂,IC50 值为 0.018 μM。MAX-10181 可用于癌症及其他相关疾病的研究。 | ||||
| GC69705 | Physalin A | 23027-91-0 | - | |
Physalin A 是一种从 Physalis alkekengi var franchetii 中分离出来的 withanolide。 Physalin A 诱导细胞凋亡 (apoptosis) 与 caspase-3 和 caspase-8 表达上调相关的。Physalin A 诱导自噬,发现可拮抗 HT1080 细胞的凋亡。Physalin A具有研究癌症疾病的潜力。 | ||||
| GC69795 | (Rac)-BIO8898 | 402564-79-8 | - | |
(Rac)-BIO8898 是一种 CD40-CD154 共刺激相互作用抑制剂。(Rac)-BIO8898 抑制 CD154 与 CD40-Ig 结合,IC50 为 25 μM。 | ||||
| GC69801 | Ragifilimab | 2207590-51-8 | >95.00% | |
Ragifilimab (INCAGN-1876) 是一种靶向糖皮质激素诱导的 TNFR 相关蛋白 (GITR) 的激动剂单克隆抗体。Ragifilimab 可用于晚期或转移性实体瘤研究。 | ||||
| GC69841 | Rubropunctatin | 514-67-0 | >98.00% | |
Rubropunctatin 是一种从红曲霉发酵米(红霉米)提取物中分离出来的橙色的氮杂酮类色素。 Rubropunctatin 具有抗炎,免疫抑制和抗氧化作用,还具有抗肿瘤活性。 | ||||
| GC69884 | Shepherdin (79-87) (TFA) | - | >98.00% | |
Shepherdin (79-87) TFA 是 Shepherdin 的 79 至 87 氨基酸片段。Shepherdin 是一种 Hsp90-Survivin 复合物的拟肽拮抗剂。具有抗肿瘤活性。 | ||||
| GC69899 | SIRT6 activator 12q | 2601734-99-8 | >98.00% | |
SIRT6 activator 12q是一种SIRT6选择性激活剂(IC 50 =0.58μM)。 | ||||
| GC69912 | SLC7A11-IN-1 | - | >95.00% | |
SLC7A11-IN-1 是一种有效的SLC7A11 抑制剂。SLC7A11-IN-1 显示出抗增殖活性。SLC7A11-IN-1 抑制细胞侵袭和转移。SLC7A11-IN-1 诱导细胞凋亡 (Apoptosis) 和细胞周期停滞在 S 期。SLC7A11-IN-1 具有抗肿瘤活性。 | ||||
| GC69934 | Spartalizumab | 1935694-88-4 | >98.00% | |
Spartalizumab (PDR001) 是一种人源化的免疫球蛋白 4 单克隆抗体,以亚纳摩尔活性结合 PD-1,并阻断与 PD-L1 和 PD-L2 的相互作用。Spartalizumab 可用于甲状腺未分化癌 (ATC) 的研究。 | ||||
| GC69968 | Sulanemadlin | 1451199-98-6 | >95.00% / >96.50% | |
Sulanemadlin是一种基于p53靶点的膜渗透性强效大环拟肽化合物,是一种稳定的α-螺旋肽。 | ||||
| GC70026 | Thymidine 3',5'-diphosphate tetrasodium | 118675-87-9 | >97.00% | |
Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium 是葡萄球菌核酸酶和含有 1 的都铎结构域 (SND1,MicroRNA 调控复合体 RISC 亚基) 与 [3,5-2H2] 酪氨酸核酸酶 ( [3,5-2H2] tyrosyl nuclease) 的选择性抑制剂。Thymidine 3',5'-diphosphate tetrasodium 具有抗肿瘤活性,在生化反应也可用作催化剂。 | ||||
| GC70039 | TNF-α (46-65), human TFA | - | - | |
TNF-α (46-65), human (TFA) 是人 TNF-α 的多肽片段。 | ||||
| GC70104 | Utomilumab | 1417318-27-4 | >99.00% | |
Utomilumab (PF 05082566) 是一种人源化的 IgG2 mAb 激动剂,靶向T 细胞共刺激受体 4-1BB/CD137。Utomilumab 可用于复发/难治性滤泡性淋巴瘤 (FL) 和其他 CD20+ 非霍奇金淋巴瘤 (NHL) 的研究。 | ||||
| GC70114 | Venetoclax-d8 | 1257051-06-1 | >99.00% | |
Venetoclax-d8 是 Venetoclax 氘代物。Venetoclax (ABT-199; GDC-0199) 是一种高效,有选择性和口服有效的 Bcl-2 抑制剂,Ki 小于0.01 nM。Venetoclax 可以诱导自噬 (autophagy) 作用。 | ||||
| GC70137 | Vudalimab | 2329669-72-7 | >99.00% | |
Vudalimab 是一种有效的 PD-1 和 CTLA-4 双重抑制剂,是一种完全人源化的双特异性单克隆抗体。Vudalimab 靶向免疫检查点受体 PD-1 和 CTLA-4,促进肿瘤选择性 T 细胞激活。 | ||||
| GC70145 | WL12 | - | >98.00% | |
WL12 是一种特异性靶向程序性死亡配体 1 (PD-L1) 结合肽。WL12 可以通过不同的放射性核素进行放射性标记,产生放射性示踪剂,评估肿瘤 PD-L1 的表达。 | ||||
| GC70154 | Yakuchinone A | 78954-23-1 | >97.00% | |
Yakuchinone A 是一种可以从 Alpinia oxyphylla 果实分离得到的天然产物,可以诱导细胞凋亡 (apoptosis),具有抗癌、抗炎活性。 | ||||
| GC70242 | Thymocartin TFA | - | 不显示 | |
Thymocartin TFA是胸腺素的TFA盐形式。 | ||||
| GC70257 | Gallium maltolate | 108560-70-9 | >98.00% | |
Gallium maltolate(GAM)是一种具有抗癌和抗炎活性的细胞凋亡诱导剂。 | ||||
